Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa
This study compares different antibiotic treatments for difficult-to-treat Pseudomonas aeruginosa infections. Researchers will evaluate how well newer antibiotics work compared to traditional options to find the most effective treatment approach.
Key Objective: This trial tests whether newer antibiotic combinations can more effectively treat resistant Pseudomonas infections compared to older standard treatments.
Who to Consider: Patients with confirmed difficult-to-treat Pseudomonas aeruginosa infections who need antimicrobial therapy should consider enrolling.
Trial Parameters
Brief Summary
The primary objective of the ADDICT study is to assess and compare the clinical efficacy of available options for antimicrobial therapy (new beta-lactam/beta-lactamase inhibitor combination, cefiderocol or older agents such as aminoglycosides and colistin) in unselected patients with infection due to difficult-to-treat P. aeruginosa.
Eligibility Criteria
Inclusion Criteria: * All patients aged 18 or over and requiring intravenous definite antimicrobial therapy for a DTR P. aeruginosa infection Exclusion Criteria: * Cystic fibrosis * P. aeruginosa DTR colonization or P. aeruginosa DTR infection not requiring definitive intravenous antibiotic therapy * Protected person (under guardianship or curatorship) * Persons under court protection * Persons deprived of liberty * Opposition expressed for participation in the study